Gladstone Institutional Advisory LLC
Position in VKTX — Viking Therapeutics, Inc.
CIK 1766530
Bedminster, NJ
Position in VKTX
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$310,822
+$31,951 QoQ
Shares Held
9,552
+20.5% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in VKTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Gladstone Institutional Advisory LLC holds $2,203,514 across 10 Biotechnology names. VKTX ranks #3 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
6,091 | $573,284 | |
| 2 | IBRX |
ImmunityBio, Inc.
|
51,418 | $394,376 | |
| 3 | VKTX |
Viking Therapeutics, Inc.
This page
|
9,552 | $310,822 | |
| 4 | SRPT |
Sarepta Therapeutics, Inc.
|
13,885 | $302,137 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
383 | $295,921 | |
| 6 | AVXL |
Anavex Life Sciences Corp.
|
72,381 | $222,209 | |
| 7 | GALT |
Galectin Therapeutics Inc
|
23,900 | $66,681 | |
| 8 | CRDF |
Cardiff Oncology, Inc.
|
13,000 | $21,060 |
All Filings in VKTX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $310,822 | 9,552 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $278,871 | 7,927 | Shares | Sole | 2026-02-17 | |
| 2024-03-31 | $295,610 | 3,605 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||